Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CLPP | Q16740 | 11/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | TCF7 | P36402 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14503911 | 0.94 | BACE1 (0.39) | SIGMAR1CLPPTSHRMEN1KMT2A | |
| SCHEMBL17572699 | 0.92 | CLPP (0.39) | CLPPKMT2AALDH1A1CTNNB1TCF7 | |
| SCHEMBL14308200 | 0.90 | KMT2A (0.39) | SIGMAR1CLPPMEN1KMT2AALDH1A1 | |
| SCHEMBL14309463 | 0.90 | KMT2A (0.41) | TSHRMEN1KMT2AALDH1A1GAA | |
| SCHEMBL13774130 | 0.89 | SIGMAR1 (0.37) | SIGMAR1CLPPRIPK1TSHRMEN1 | |
| SCHEMBL14309925 | 0.89 | SIGMAR1 (0.37) | SIGMAR1CLPPRIPK1TSHRMEN1 | |
| SCHEMBL13774234 | 0.89 | CLPP (0.48) | CLPPCTNNB1TCF7 | |
| SCHEMBL14319224 | 0.88 | CLPP (0.36) | CLPPALDH1A1CTNNB1TCF7 | |
| SCHEMBL14309930 | 0.88 | CLPP (0.39) | CLPPMEN1KMT2AALDH1A1GAA | |
| SCHEMBL14309433 | 0.88 | CACNA1G (0.41) | CLPPTSHRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957516-B1 | ALFA-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS | CHOONGWAE PHARMA CORP (KR) | 2016-03-09 | — | — | EP | disclosed |
| US-20140209874-A1 | ORGANIC LIGHT EMITTING DIODE | SAMSUNG DISPLAY CO., LTD. (KR) | 2014-07-31 | — | — | US | disclosed |
| US-20090176742-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080242669-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | INSTITUTE FOR CHEMICAL GENOMICS | 2008-01-10 | — | — | US | disclosed |
| US-20070129353-A1 | Alpha-helix mimetics and method relating to the treatment of cancer stem cells | INSTITUTE FOR CHEMICAL GENOMICS | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | COL1A1, COL2A1, PLOD3 | SIGMAR1 2975/4885CLPP 2188/4885RIPK1 2376/4885 |
| US-20080242669-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | NR3C1, RXFP3, NR2E3 | SIGMAR1 85/4885CLPP 4872/4885RIPK1 1896/4885 |
| US-20070129353-A1 | Alpha-helix mimetics and method relating to the treatment of cancer stem cells | MCL1, HNF4A, THPO | SIGMAR1 3670/4885CLPP 2482/4885RIPK1 3485/4885 |
| US-20090176742-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | RXFP3, NR3C1, NR2E3 | SIGMAR1 80/4885CLPP 4874/4885RIPK1 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.